Bokf Na Has $1.79 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bokf Na lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.6% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,845 shares of the biopharmaceutical company’s stock after selling 30 shares during the period. Bokf Na’s holdings in Regeneron Pharmaceuticals were worth $1,788,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. West Paces Advisors Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares during the period. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $28,000. MCF Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 12 shares during the period. Criterion Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $37,000. Finally, BOK Financial Private Wealth Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $37,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald lifted their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $1,000.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Barclays lifted their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Argus lifted their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Finally, StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $1,074.95.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,137 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the transaction, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the sale, the executive vice president now directly owns 12,931 shares in the company, valued at approximately $13,540,179.41. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,074 shares of company stock worth $64,546,123. 7.48% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded up $14.44 on Friday, hitting $1,078.63. 380,897 shares of the company were exchanged, compared to its average volume of 386,591. The company’s 50 day moving average price is $1,033.85 and its two-hundred day moving average price is $977.31. Regeneron Pharmaceuticals, Inc. has a one year low of $723.56 and a one year high of $1,106.16. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The firm has a market capitalization of $118.85 billion, a price-to-earnings ratio of 31.87, a PEG ratio of 2.22 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.36 earnings per share for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.